Paratek pharmaceuticals to acquire optinose, creating significant commercial expansion opportunities for xhance® in chronic rhinosinusitis (crs)

Paratek will accelerate access for xhance beyond specialists to primary care providers maximizing the recent label expansion for crs in a ~10 ‑ million ‑ patient market acquisition advances paratek's vision to become a multi-product company focused on innovative specialty therapies total transaction value of up to ~$330 million potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to optinose's closing trading price on march 19, 2025 boston and yardley, pa., march 19, 2025 (globe newswire) -- paratek pharmaceuticals and optinose, inc. (nasdaq:optn) today announced they have entered into a definitive merger agreement under which paratek will acquire optinose, including its approved product xhance ® (fluticasone propionate).
CRS Ratings Summary
CRS Quant Ranking